Tucatinib

Unassigned

New Medicines

Locally advanced unresectable or metastatic HER2-positive breast cancer in patients previously treated with trastuzumab, pertuzumab and T-DM1 - with capecitabine and trastuzumab

Information

New molecular entity
Array BioPharma
Array BioPharma

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Oral tyrosine kinase inhibitor selective for HER2 (ERBB-2 receptor) - prevents activation of ERBB-2 signal transduction pathways, and results in the growth inhibition and death of HER2/ERBB-2-expressing tumour cells.[3,4]
In the UK, it is estimated that there are ~55200 new cases of invasive breast cancer per year based on averages between 2014 and 2016.[1] Between 15-20% of cases are HER2+. [2,3]
Locally advanced unresectable or metastatic HER2-positive breast cancer in patients previously treated with trastuzumab, pertuzumab and T-DM1 - with capecitabine and trastuzumab
Oral